Copper's Essential Role in Metabolic Health

Copper stands as one of the body's most versatile trace minerals, participating in a wide array of physiological processes that extend far beyond its well-known roles in red blood cell formation and immune defense. Emerging research has positioned copper as a critical modulator of glucose metabolism, directly influencing both the production of insulin by pancreatic beta cells and the hormone's ability to facilitate glucose uptake in peripheral tissues. This dual involvement makes copper status a meaningful factor in metabolic health, with implications for diabetes prevention and management.

The relationship between copper and insulin operates through multiple interconnected pathways, including enzymatic catalysis, antioxidant defense, and inflammatory signaling. A growing body of evidence indicates that maintaining copper within an optimal range supports healthy insulin secretion, preserves insulin receptor sensitivity, and protects against the oxidative stress that characterizes insulin-resistant states. This article examines the mechanistic links between copper and insulin action, reviews clinical evidence connecting copper status to metabolic outcomes, and provides practical guidance for achieving adequate copper intake through diet.

Copper Biochemistry in Human Physiology

Enzymatic Functions and Systemic Roles

Copper functions primarily as a catalytic cofactor for a diverse set of enzymes known as cuproenzymes. These enzymes mediate reactions essential for energy production, neurotransmitter synthesis, connective tissue formation, and iron mobilization. Cytochrome c oxidase, a copper-dependent enzyme in the mitochondrial electron transport chain, is indispensable for aerobic respiration and ATP generation. In tissues with high metabolic demand, such as skeletal muscle and the pancreas, adequate copper is required to maintain efficient energy production.

Another crucial cuproenzyme, superoxide dismutase (SOD), exists in two forms: the copper-zinc SOD found in the cytosol and the manganese SOD found in mitochondria. Cu/Zn-SOD provides the first line of defense against superoxide radicals, converting them to hydrogen peroxide, which is then neutralized by catalase and glutathione peroxidase. This antioxidant function is particularly important in beta cells, which express relatively low levels of endogenous antioxidant enzymes and are therefore vulnerable to oxidative injury.

Ceruloplasmin, a copper-containing ferroxidase, plays a central role in iron homeostasis by oxidizing ferrous iron to ferric iron, enabling its binding to transferrin and subsequent transport to tissues. Without adequate ceruloplasmin activity, iron accumulates in cells, promoting Fenton chemistry that generates highly reactive hydroxyl radicals. This iron-driven oxidative stress can damage cellular membranes, proteins, and DNA, including components of the insulin signaling cascade.

Copper Homeostasis and Distribution

The body maintains copper balance through tightly regulated mechanisms involving intestinal absorption, hepatic storage, and biliary excretion. Dietary copper is absorbed primarily in the small intestine via the copper transporter CTR1, with absorption efficiency varying inversely with dietary intake. Once absorbed, copper is transported to the liver bound to albumin and transcuprein, where it is incorporated into ceruloplasmin for distribution to peripheral tissues or stored in metallothionein pools.

Copper chaperones direct copper to specific cellular compartments: CCS delivers copper to Cu/Zn-SOD in the cytosol, ATOX1 transports copper to the secretory pathway for incorporation into ceruloplasmin, and COX17 directs copper to the mitochondria for cytochrome c oxidase assembly. Genetic defects in these chaperone systems, such as mutations in ATP7A causing Menkes disease, produce severe copper deficiency states characterized by progressive neurological degeneration and connective tissue abnormalities.

Serum copper concentrations typically range from 70 to 140 micrograms per deciliter, with approximately 90 percent bound to ceruloplasmin. The remaining 10 percent, referred to as exchangeable or labile copper, represents the biologically active fraction that participates in cellular signaling. Measurement of exchangeable copper provides a more physiologically relevant assessment of copper status than total serum copper alone, particularly in conditions associated with altered ceruloplasmin levels such as inflammation and diabetes.

Copper and Insulin Production

Beta-Cell Integrity and Secretory Capacity

Pancreatic beta cells are specialized endocrine cells responsible for synthesizing, storing, and secreting insulin in response to glucose and other secretagogues. The insulin secretory machinery depends on intact mitochondrial function, calcium signaling, and vesicle trafficking, all of which require copper-dependent enzymatic activity. Copper deficiency reduces ATP production in beta cells by impairing cytochrome c oxidase activity, limiting the energy available for insulin granule exocytosis.

Animal studies have demonstrated that copper-deficient diets decrease pancreatic insulin content and impair glucose-stimulated insulin secretion. Rats fed copper-restricted diets exhibit reduced beta-cell mass and diminished insulin release in response to both glucose and non-glucose secretagogues such as arginine. These effects are partially reversible with copper repletion, suggesting that copper is required for maintaining the structural and functional integrity of beta cells.

Copper also influences beta-cell survival through its role in regulating apoptosis. The antioxidant activity of Cu/Zn-SOD protects beta cells from the cytotoxic effects of hyperglycemia-induced oxidative stress, which activates endoplasmic reticulum stress pathways and caspase-dependent cell death. In cell culture models, copper supplementation increases Cu/Zn-SOD activity and reduces beta-cell apoptosis under glucotoxic conditions, while copper chelation sensitizes beta cells to oxidative injury.

Enzymatic Processing of Proinsulin

Insulin is initially synthesized as preproinsulin, which undergoes proteolytic cleavage in the endoplasmic reticulum to produce proinsulin. Proinsulin is then transported to the Golgi apparatus, where it is packaged into secretory granules and processed by prohormone convertases PC1/3 and PC2 to yield mature insulin and C-peptide. The activity of these convertases is influenced by the redox environment within the secretory pathway, which is modulated by copper-dependent enzymes.

The cuproenzyme tyrosinase, best known for its role in melanin synthesis, has been implicated in the post-translational modification of proteins involved in insulin processing. While tyrosinase is not directly responsible for proinsulin cleavage, its activity contributes to the proper folding and stabilization of secretory proteins within the Golgi. Disruption of copper homeostasis in this compartment can lead to misfolded proinsulin accumulation and endoplasmic reticulum stress, triggering the unfolded protein response and reducing insulin production.

Copper also affects the expression of the transcription factor pancreatic and duodenal homeobox 1 (PDX-1), which regulates insulin gene transcription and beta-cell differentiation. PDX-1 binds to the insulin promoter and activates transcription in response to glucose stimulation. Copper deficiency reduces PDX-1 nuclear localization and DNA-binding activity, leading to decreased insulin mRNA levels. This finding underscores the importance of copper for maintaining the transcriptional machinery that drives insulin synthesis.

Copper and Beta-Cell Mass Regulation

Beyond its effects on insulin secretion and synthesis, copper influences the maintenance and expansion of beta-cell mass. Beta-cell mass is dynamically regulated through the balance of replication, neogenesis, and apoptosis. Copper-dependent signaling pathways, including those involving the mitogen-activated protein kinase (MAPK) cascade, modulate beta-cell proliferation in response to metabolic demands.

In models of insulin resistance, the compensatory increase in beta-cell mass requires adequate copper to support the biosynthetic demands of enhanced insulin production. Copper deficiency limits this adaptive response, accelerating the progression from insulin resistance to overt hyperglycemia. Conversely, copper excess can also impair beta-cell function by promoting the formation of advanced glycation end products and amyloid deposits, which contribute to beta-cell toxicity in type 2 diabetes.

Copper and Insulin Action

Insulin Receptor Signaling Cascade

Insulin action begins with the binding of insulin to its cell surface receptor, a tyrosine kinase receptor composed of two extracellular alpha subunits and two transmembrane beta subunits. Ligand binding induces conformational changes that activate the intrinsic tyrosine kinase activity of the beta subunits, leading to autophosphorylation and subsequent phosphorylation of insulin receptor substrate (IRS) proteins. These phosphorylated IRS proteins serve as docking sites for downstream signaling molecules, including phosphatidylinositol 3-kinase (PI3K), which activates the Akt pathway that mediates glucose uptake, glycogen synthesis, and inhibition of gluconeogenesis.

Copper status modulates each step of this signaling cascade. The activity of the insulin receptor tyrosine kinase is sensitive to the cellular redox state, with oxidative stress promoting receptor desensitization through oxidation of critical cysteine residues. Cu/Zn-SOD protects these residues from oxidative modification by maintaining low intracellular superoxide levels. In copper-deficient states, reduced SOD activity allows superoxide accumulation, which inhibits insulin receptor autophosphorylation and decreases downstream signaling through the PI3K/Akt pathway.

IRS-1 and IRS-2 are particularly vulnerable to oxidative modification and serine phosphorylation, which converts them from activators of insulin signaling to inhibitors. Serine phosphorylation of IRS proteins targets them for proteasomal degradation and disrupts their interaction with PI3K. Copper deficiency promotes this inhibitory phosphorylation by activating stress-sensitive kinases such as JNK and IKK-beta, which are stimulated by reactive oxygen species. This mechanism represents a direct link between copper status and insulin resistance at the molecular level.

GLUT4 Translocation and Glucose Uptake

Glucose transporter 4 (GLUT4) is the primary insulin-responsive glucose transporter expressed in skeletal muscle, adipose tissue, and cardiac muscle. In the basal state, GLUT4 is sequestered in intracellular vesicles; insulin stimulation triggers its translocation to the plasma membrane, where it facilitates glucose entry into the cell. This translocation process requires an intact actin cytoskeleton, proper vesicle trafficking machinery, and appropriate membrane lipid composition, all of which are influenced by copper availability.

Copper contributes to GLUT4 translocation through its effects on membrane fluidity and lipid raft organization. Cholesterol-rich membrane microdomains known as lipid rafts serve as platforms for insulin signaling and GLUT4 vesicle docking. Copper alters membrane lipid composition by modulating the activity of desaturases involved in fatty acid metabolism. Copper deficiency increases membrane saturation and reduces fluidity, impairing the lateral mobility of insulin receptors and the fusion of GLUT4 vesicles with the plasma membrane.

Studies in copper-deficient rats have demonstrated a 40 to 50 percent reduction in insulin-stimulated glucose uptake in skeletal muscle compared to copper-adequate controls. This impairment correlates with decreased GLUT4 translocation to the plasma membrane and reduced Akt phosphorylation. Importantly, these defects occur independently of changes in total GLUT4 expression, indicating that copper deficiency specifically disrupts the translocation machinery rather than reducing glucose transporter abundance.

Inflammation and Oxidative Stress Pathways

Chronic low-grade inflammation represents a central mechanism linking copper imbalance to insulin resistance. Adipose tissue expansion in obesity recruits immune cells that secrete pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), which activate serine kinases that phosphorylate IRS proteins and impair insulin signaling. Copper modulates this inflammatory response through its effects on redox-sensitive transcription factors.

Nuclear factor kappa-B (NF-kappaB) is a master regulator of inflammatory gene expression that is activated by oxidative stress. Under normal conditions, NF-kappaB is sequestered in the cytoplasm by its inhibitor I-kappaB. Reactive oxygen species activate I-kappaB kinase, which phosphorylates I-kappaB, leading to its degradation and NF-kappaB nuclear translocation. Copper deficiency reduces Cu/Zn-SOD activity, allowing superoxide to accumulate and activate this pathway, thereby amplifying inflammatory signaling.

Copper also influences the activity of peroxisome proliferator-activated receptor gamma (PPAR-gamma), a nuclear receptor that promotes insulin sensitivity and adipocyte differentiation. PPAR-gamma ligands, including thiazolidinedione drugs, improve insulin sensitivity by reducing inflammatory gene expression and enhancing fatty acid storage. Copper affects PPAR-gamma activity by modulating the redox state of its ligand-binding domain and by influencing the expression of its coactivators. Copper deficiency reduces PPAR-gamma target gene expression in adipose tissue, contributing to impaired insulin action.

Clinical Evidence Linking Copper to Metabolic Outcomes

Epidemiological Studies and Observational Data

Population-based studies have reported associations between circulating copper levels and markers of glucose metabolism, although the direction of these associations varies depending on the population studied and the methods used to assess copper status. Several cross-sectional studies have found lower serum copper concentrations in individuals with type 2 diabetes compared to healthy controls, with the magnitude of reduction correlating with glycemic control as measured by hemoglobin A1c.

A meta-analysis of observational studies examining trace element levels in type 2 diabetes found that serum copper was significantly lower in diabetic patients in studies conducted in regions with marginal copper intake, but higher in studies from populations with adequate to high copper intake. This pattern suggests that the relationship between copper and diabetes is nonlinear and context-dependent, with both deficiency and excess associated with increased risk depending on baseline nutritional status.

Longitudinal cohort studies have provided evidence that low copper intake precedes the development of impaired glucose tolerance. In the Coronary Artery Risk Development in Young Adults (CARDIA) study, lower dietary copper intake at baseline was associated with a higher incidence of metabolic syndrome over 20 years of follow-up. Similar findings have been reported in European cohorts, where low serum copper predicted progression from normoglycemia to prediabetes independent of age, sex, and body mass index.

Copper Status in Type 2 Diabetes: Deficiency versus Excess

The apparent paradox of both low and high copper being reported in type 2 diabetes can be resolved by distinguishing between total serum copper and exchangeable copper. Total serum copper is largely determined by ceruloplasmin concentrations, which rise during inflammation. Since type 2 diabetes is characterized by chronic low-grade inflammation, many diabetic patients exhibit elevated ceruloplasmin and total copper levels. However, the exchangeable copper fraction may be reduced due to impaired copper mobilization from ceruloplasmin or increased urinary copper loss.

Urinary copper excretion is elevated in individuals with poorly controlled diabetes, likely due to glucose-induced osmotic diuresis and tubular dysfunction. This urinary loss can deplete body copper stores over time, particularly in patients with inadequate dietary intake. The combination of increased ceruloplasmin-driven total copper and decreased tissue copper availability represents a state of functional copper deficiency masked by inflammatory changes in circulating biomarkers.

Diabetic complications, including nephropathy, retinopathy, and cardiovascular disease, are associated with increased free copper levels in affected tissues. Copper accumulates in the kidneys and retina of diabetic animals, where it catalyzes the formation of reactive oxygen species and promotes tissue damage. Clinical studies have shown that diabetic patients with albuminuria have higher urinary copper excretion and elevated kidney copper content compared to those without nephropathy. These observations suggest that copper redistribution, rather than simple deficiency or excess, characterizes the diabetic state.

Intervention Studies and Supplementation Trials

Randomized controlled trials examining the effects of copper supplementation on glucose metabolism have produced mixed results, reflecting differences in baseline copper status, supplementation dose, and study duration. In trials enrolling individuals with confirmed copper deficiency, copper supplementation at doses of 2 to 3 milligrams per day for 8 to 12 weeks has been shown to improve insulin sensitivity and reduce fasting glucose. These benefits are most pronounced in populations with marginal copper intake, such as the elderly and those consuming zinc-fortified diets.

A clinical trial involving patients with type 2 diabetes and low serum copper reported that copper supplementation improved glycemic control and reduced oxidative stress markers compared to placebo. Participants receiving 2 milligrams of copper as copper glycinate for 12 weeks showed significant reductions in fasting glucose and hemoglobin A1c, along with increased Cu/Zn-SOD activity and decreased malondialdehyde levels. These findings support the concept that correcting copper deficiency can improve metabolic outcomes in affected individuals.

However, copper supplementation in individuals with adequate or elevated copper status does not improve insulin sensitivity and may worsen oxidative stress. A study of copper supplementation at 3 milligrams per day in healthy adults with normal baseline copper levels found no change in insulin sensitivity and a small increase in DNA oxidative damage markers. This highlights the importance of assessing individual copper status before initiating supplementation and reinforces the principle that more is not better when it comes to copper nutrition.

Dietary Modulation of Copper Status

Food Sources and Bioavailability

Copper is widely distributed in the food supply, with the richest sources including organ meats, shellfish, nuts, seeds, and whole grains. Beef liver is one of the most concentrated dietary sources, providing approximately 12 milligrams of copper per 100 grams, or more than 1,300 percent of the daily value. Oysters, crab, and lobster provide 2 to 6 milligrams per serving, making them valuable sources for those who consume seafood. Among plant foods, sunflower seeds, cashews, almonds, and sesame seeds provide between 0.5 and 1.5 milligrams per ounce.

The bioavailability of copper from food varies considerably depending on the food matrix and the presence of enhancers or inhibitors of absorption. Copper from animal sources is generally well absorbed, with bioavailability estimates of 60 to 75 percent. Plant-based copper is less bioavailable, with absorption rates of 30 to 50 percent, due to the presence of phytic acid and fiber that bind copper and reduce its solubility in the intestinal lumen. Soaking, sprouting, and fermenting grains and legumes can reduce phytate content and improve copper absorption from these foods.

Vitamin C enhances copper absorption by maintaining copper in its reduced cuprous form, which is more readily transported across the intestinal epithelium. Consuming copper-rich foods with vitamin C-rich foods, such as citrus fruits, bell peppers, or broccoli, can increase copper bioavailability. Conversely, high doses of zinc, iron, and molybdenum compete with copper for absorption and can induce deficiency when consumed in excess. Zinc supplementation at doses above 40 milligrams per day is a well-established cause of copper deficiency in clinical practice.

The recommended dietary allowance for copper is 900 micrograms per day for adult men and women, with higher requirements during pregnancy (1,000 micrograms) and lactation (1,300 micrograms). The tolerable upper intake level is 10,000 micrograms per day, although most individuals can meet their needs through diet alone without approaching this limit. Dietary surveys indicate that mean copper intake in the United States is approximately 1,100 to 1,200 micrograms per day for men and 900 to 1,000 micrograms per day for women, suggesting that most adults meet the RDA through typical dietary patterns.

Assessment of copper status requires careful interpretation of multiple biomarkers, as no single test provides a complete picture. Serum copper and ceruloplasmin are the most commonly measured indicators, but both are acute-phase reactants that increase during inflammation, infection, and estrogen therapy. Serum copper concentrations below 70 micrograms per deciliter and ceruloplasmin levels below 15 milligrams per deciliter suggest copper deficiency, while levels above these cutoffs do not rule out functional deficiency when inflammation is present.

Measurement of erythrocyte Cu/Zn-SOD activity provides a more stable indicator of long-term copper status, as red blood cell enzyme levels reflect copper availability over the preceding several weeks. Erythrocyte SOD activity decreases in copper deficiency and responds slowly to supplementation, making it a useful marker for monitoring repletion. Other markers, including plasma copper chaperone levels and urinary copper excretion, are used primarily in research settings but may become clinically available as the understanding of copper metabolism advances.

Factors Affecting Copper Requirements

Several physiological and dietary factors increase copper requirements and predispose individuals to deficiency. High fructose consumption, a hallmark of Western dietary patterns, impairs copper absorption and retention in animal models. Fructose metabolism in the liver generates uric acid and increases oxidative stress, which may accelerate copper utilization and excretion. In human studies, diets high in fructose have been associated with lower serum copper and reduced Cu/Zn-SOD activity, particularly when copper intake is marginal.

Zinc supplementation is one of the most common causes of copper deficiency in clinical practice. Zinc induces the expression of metallothionein in intestinal enterocytes, a protein that binds copper with high affinity and prevents its transfer into the circulation. Zinc-induced copper deficiency can develop within weeks of initiating high-dose zinc therapy and may persist for months after discontinuation. Individuals taking zinc supplements for acne, age-related macular degeneration, or immune support should ensure adequate copper intake and consider periodic monitoring of copper status.

Gastrointestinal conditions that impair nutrient absorption, including celiac disease, Crohn's disease, and gastric bypass surgery, increase the risk of copper deficiency. Proton pump inhibitors, which reduce gastric acid secretion, can also decrease copper absorption by altering the solubility of dietary copper. Long-term use of these medications has been associated with lower serum copper levels and an increased incidence of copper deficiency-related hematologic and neurological abnormalities.

Therapeutic Approaches and Future Directions

Copper Supplementation Strategies

When copper deficiency is confirmed, supplementation should be tailored to the underlying cause and the severity of the deficiency. Oral copper supplementation at doses of 2 to 4 milligrams per day is typically sufficient for mild to moderate deficiency, with higher doses reserved for severe cases or malabsorptive conditions. Copper gluconate, copper sulfate, and copper glycinate are common supplement forms, with copper glycinate showing superior bioavailability in some studies due to its chelated structure that reduces competition with other minerals for absorption.

Supplementation should continue until copper biomarkers normalize, which typically requires 4 to 8 weeks for serum copper and 2 to 4 months for erythrocyte SOD activity. Long-term maintenance therapy may be necessary for individuals with persistent malabsorption or ongoing losses. Copper supplementation should be administered separately from high-dose zinc supplements to minimize competitive inhibition, ideally with at least 2 hours between doses.

Intravenous copper is reserved for patients with severe deficiency who cannot absorb oral supplements, such as those with short bowel syndrome or extensive gastric resection. Copper chloride added to parenteral nutrition solutions provides approximately 0.3 to 0.5 milligrams per day for maintenance, with higher doses used for repletion. Intravenous copper administration requires careful monitoring to avoid toxicity, as the absence of intestinal regulation can lead to rapid elevations in circulating copper levels.

Copper Chelation in Diabetic Complications

Excess tissue copper contributes to the pathogenesis of diabetic complications through oxidative damage and impaired mitochondrial function. Copper chelation therapy using agents such as trientine, tetrathiomolybdate, or D-penicillamine has shown promise in preclinical models for reducing albuminuria, improving cardiac function, and preserving retinal integrity. These agents bind excess copper with high affinity and promote its urinary excretion, reducing the labile copper pool available to catalyze free radical formation.

Clinical trials of trientine in patients with diabetic cardiomyopathy have demonstrated improvements in left ventricular mass and ejection fraction over 12 months of treatment. These benefits correlated with reductions in urinary copper excretion and decreases in circulating markers of oxidative stress. Similar studies in diabetic nephropathy have shown that trientine reduces proteinuria and slows the decline in glomerular filtration rate, although larger trials are needed to confirm these findings and establish safety profiles for long-term use.

Copper chelation remains an investigational approach and is not currently recommended for routine management of diabetic complications. The risk of inducing copper deficiency, which could impair insulin production and worsen glycemic control, requires careful monitoring of copper status during therapy. Future research will need to identify patient populations most likely to benefit from copper reduction and establish optimal treatment protocols that balance the therapeutic benefits of copper lowering with the risks of deficiency.

Genetic and Nutrigenomic Considerations

Genetic polymorphisms in copper transport and utilization pathways influence individual susceptibility to copper deficiency and toxicity. Variations in the ATP7A and ATP7B genes, which encode copper-transporting ATPases, alter copper distribution between tissues and affect the risk of copper-related disorders. Common polymorphisms in the CTR1 copper transporter gene have been associated with differences in copper absorption efficiency and may modulate the metabolic response to dietary copper intake.

Single nucleotide polymorphisms in the SOD1 gene, which encodes Cu/Zn-SOD, affect enzyme activity and stability, with some variants conferring reduced antioxidant capacity. Individuals carrying these variants may have higher copper requirements to maintain adequate SOD activity and may be more susceptible to oxidative stress under conditions of marginal copper intake. Personalized nutrition approaches that account for genetic variation in copper metabolism could optimize copper status and improve metabolic outcomes at the individual level.

Epigenetic modifications influenced by copper status represent another frontier in understanding copper-metabolism interactions. Copper-dependent enzymes participate in the regulation of DNA methylation and histone modification, processes that influence gene expression patterns relevant to insulin sensitivity and beta-cell function. Early-life copper deficiency may program epigenetic marks that persist into adulthood and increase the risk of metabolic disease, highlighting the importance of adequate copper nutrition during critical developmental windows.

Conclusion

Copper exerts profound effects on both the production and action of insulin through its roles as an enzymatic cofactor, antioxidant defender, and signaling modulator. Adequate copper supports pancreatic beta-cell function, facilitates insulin receptor signaling, and preserves glucose transporter mobilization, while both copper deficiency and excess impair these processes and contribute to metabolic dysfunction. The relationship between copper and insulin sensitivity follows a U-shaped curve, with optimal metabolic health maintained within a relatively narrow range of copper status.

Clinical evidence indicates that copper deficiency increases the risk of impaired glucose tolerance and type 2 diabetes, particularly in populations with marginal intake or elevated requirements. Conversely, excess copper accumulation in tissues contributes to diabetic complications through oxidative damage and inflammatory activation. Therapeutic strategies aimed at normalizing copper homeostasis, whether through supplementation to correct deficiency or chelation to reduce excess, show promise for improving metabolic outcomes but require careful individualization based on accurate assessment of copper status.

A diet that includes copper-rich whole foods such as shellfish, organ meats, nuts, seeds, and legumes provides the foundation for maintaining adequate copper status without risk of excess. Awareness of factors that disrupt copper balance, including high fructose intake, zinc supplementation, and malabsorptive conditions, allows for proactive management of copper nutrition. As research continues to elucidate the molecular mechanisms linking copper to insulin action, the integration of copper assessment into metabolic health evaluation may become an increasingly valuable tool for preventing and managing diabetes.

For additional information on copper nutrition and metabolism, refer to the NIH Office of Dietary Supplements copper fact sheet, a comprehensive review of copper and diabetes pathogenesis, and the role of trace elements in insulin resistance.